Canopy Growth (NYSE:CGC) Shares Down 7.8%

Canopy Growth Corp (NYSE:CGC) traded down 7.8% during trading on Friday . The stock traded as low as $34.04 and last traded at $34.21, …

Canopy Growth logoCanopy Growth Corp (NYSE:CGC) traded down 7.8% during trading on Friday . The stock traded as low as $34.04 and last traded at $34.21, 14,116,477 shares traded hands during mid-day trading. An increase of 100% from the average session volume of 7,068,426 shares. The stock had previously closed at $37.09.

Several equities research analysts have recently commented on the company. Desjardins reissued a “buy” rating on shares of Fiera Capital in a research note on Thursday, July 4th. GMP Securities raised Canopy Growth from a “hold” rating to a “buy” rating and lifted their target price for the company from $65.00 to $72.00 in a research note on Monday, April 22nd. Stifel Nicolaus reissued a “buy” rating on shares of Canopy Growth in a research note on Wednesday, July 3rd. Evercore ISI assumed coverage on LYFT in a research note on Wednesday, June 12th. They issued an “outperform” rating and a $74.00 target price for the company. Finally, Piper Jaffray Companies set a $92.00 target price on Wintrust Financial and gave the company a “buy” rating in a research note on Monday, July 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $55.34.

The company has a debt-to-equity ratio of 0.12, a current ratio of 12.32 and a quick ratio of 11.49. The company has a 50 day simple moving average of $41.06. The company has a market capitalization of $11.83 billion, a price-to-earnings ratio of -21.52 and a beta of 3.65.

Canopy Growth (NYSE:CGC) last announced its quarterly earnings data on Thursday, June 20th. The marijuana producer reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.50). Canopy Growth had a negative return on equity of 15.82% and a negative net margin of 304.03%. The company had revenue of $70.74 million for the quarter, compared to analyst estimates of $71.06 million. Sell-side analysts predict that Canopy Growth Corp will post -0.82 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in CGC. Stone House Investment Management LLC acquired a new position in Canopy Growth in the first quarter valued at about $25,000. Ellis Investment Partners LLC acquired a new position in Canopy Growth in the first quarter valued at about $25,000. Global Retirement Partners LLC grew its stake in Canopy Growth by 524.0% in the first quarter. Global Retirement Partners LLC now owns 624 shares of the marijuana producer’s stock valued at $27,000 after acquiring an additional 524 shares during the period. Private Capital Group LLC grew its stake in Canopy Growth by 221.5% in the first quarter. Private Capital Group LLC now owns 643 shares of the marijuana producer’s stock valued at $28,000 after acquiring an additional 443 shares during the period. Finally, TCG Advisors LP acquired a new position in Canopy Growth in the first quarter valued at about $28,000. 8.05% of the stock is owned by institutional investors and hedge funds.

Canopy Growth Company Profile (NYSE:CGC)

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names.

Read More: Hedge Funds

Receive News & Ratings for Canopy Growth Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Canopy Growth and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Avianca (NYSE:AVH) Shares Up 6.9%

Two Sigma Investments LP bought a new position in Avianca during the 4th quarter worth $63,000. D. E. Shaw & Co. Inc. raised its position in Avianca …

Avianca logoAvianca Holdings SA (NYSE:AVH) shares shot up 6.9% during trading on Friday . The company traded as high as $4.35 and last traded at $4.35, 128,523 shares traded hands during mid-day trading. An increase of 3% from the average session volume of 125,133 shares. The stock had previously closed at $4.07.

A number of brokerages have recently commented on AVH. Zacks Investment Research upgraded GCP Applied Technologies from a “sell” rating to a “hold” rating in a research note on Friday, May 31st. ValuEngine cut Intersect ENT from a “buy” rating to a “hold” rating in a research note on Monday, July 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company’s stock. Avianca currently has an average rating of “Hold” and a consensus price target of $5.88.

The stock has a market cap of $359.31 million, a P/E ratio of 4.78 and a beta of 0.90. The company has a quick ratio of 0.44, a current ratio of 0.48 and a debt-to-equity ratio of 11.26. The firm’s 50 day simple moving average is $3.79.

Avianca (NYSE:AVH) last announced its quarterly earnings results on Thursday, May 16th. The transportation company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.02. Avianca had a negative return on equity of 10.46% and a negative net margin of 1.79%. The company had revenue of $1.15 billion during the quarter, compared to analysts’ expectations of $1.15 billion. As a group, research analysts forecast that Avianca Holdings SA will post -0.25 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Two Sigma Advisers LP bought a new position in Avianca during the 4th quarter worth $56,000. Two Sigma Investments LP bought a new position in Avianca during the 4th quarter worth $63,000. D. E. Shaw & Co. Inc. raised its position in Avianca by 231.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 35,313 shares of the transportation company’s stock worth $143,000 after purchasing an additional 24,664 shares during the last quarter. River & Mercantile Asset Management LLP raised its position in Avianca by 8.3% during the 1st quarter. River & Mercantile Asset Management LLP now owns 438,300 shares of the transportation company’s stock worth $1,795,000 after purchasing an additional 33,700 shares during the last quarter. Finally, Donald Smith & CO. Inc. raised its position in Avianca by 11.4% during the 1st quarter. Donald Smith & CO. Inc. now owns 2,832,272 shares of the transportation company’s stock worth $11,612,000 after purchasing an additional 289,967 shares during the last quarter. 5.89% of the stock is owned by institutional investors and hedge funds.

Avianca Company Profile (NYSE:AVH)

Avianca Holdings SA, through its subsidiaries, provides passenger and cargo air transportation services in North America, Central America, the Caribbean, Colombia, Europe, South America, and internationally. It also offers aircraft maintenance, crew training, and other airport services to other carriers, as well as travel and cargo related services to its customers.

Read More: What are the FAANG Stocks?

Receive News & Ratings for Avianca Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Avianca and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Verastem (NASDAQ:VSTM) Lifted to Hold at Zacks Investment Research

Two Sigma Investments LP boosted its position in Verastem by 1,540.3% during the 4th quarter. Two Sigma Investments LP now owns 1,235,176 …

Verastem Inc logoZacks Investment Research upgraded shares of Verastem (NASDAQ:VSTM) from a sell rating to a hold rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, “Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. “

A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald started coverage on shares of Verastem in a research note on Wednesday, April 3rd. They issued an overweight rating and a $5.00 price target on the stock. HC Wainwright set a $12.00 price target on shares of IMV and gave the company a buy rating in a research note on Friday, May 10th. ValuEngine downgraded shares of Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. BTIG Research raised their price target on shares of Innovative Industrial Properties to $148.00 and gave the company a buy rating in a research note on Thursday, June 20th. Finally, B. Riley restated a buy rating and issued a $26.00 price target (up from $24.00) on shares of KEMET in a research note on Thursday, May 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $7.66.

VSTM opened at $1.51 on Friday. The firm has a 50 day moving average of $1.43. Verastem has a 1-year low of $1.16 and a 1-year high of $10.35. The company has a current ratio of 7.57, a quick ratio of 7.56 and a debt-to-equity ratio of 1.42. The firm has a market cap of $111.55 million, a P/E ratio of -1.10 and a beta of 2.98.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.05). Verastem had a negative net margin of 315.21% and a negative return on equity of 79.68%. The company had revenue of $1.67 million during the quarter, compared to analyst estimates of $2.84 million. On average, equities analysts predict that Verastem will post -1.97 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Verastem by 21.0% during the 4th quarter. BlackRock Inc. now owns 5,621,011 shares of the biopharmaceutical company’s stock worth $18,886,000 after buying an additional 976,123 shares during the period. Millennium Management LLC boosted its position in Verastem by 2,376.5% during the 4th quarter. Millennium Management LLC now owns 1,248,037 shares of the biopharmaceutical company’s stock worth $4,193,000 after buying an additional 1,197,642 shares during the period. Two Sigma Investments LP boosted its position in Verastem by 1,540.3% during the 4th quarter. Two Sigma Investments LP now owns 1,235,176 shares of the biopharmaceutical company’s stock worth $4,150,000 after buying an additional 1,159,874 shares during the period. Dimensional Fund Advisors LP boosted its position in Verastem by 98.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,085,135 shares of the biopharmaceutical company’s stock worth $3,646,000 after buying an additional 539,193 shares during the period. Finally, Two Sigma Advisers LP boosted its position in Verastem by 711.1% during the 4th quarter. Two Sigma Advisers LP now owns 256,300 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 224,700 shares during the period. Institutional investors and hedge funds own 43.83% of the company’s stock.

Verastem Company Profile

Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Read More: Why is Cost of Capital Important?

Get a free copy of the Zacks research report on Verastem (VSTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Verastem and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Apyx Medical Corp (NASDAQ:APYX) Receives $8.00 Consensus Target Price from Brokerages

Finally, WINTON GROUP Ltd purchased a new position in Apyx Medical during the 2nd quarter valued at about $79,000. 45.39% of the stock is owned …

Apyx Medical logoShares of Apyx Medical Corp (NASDAQ:APYX) have been given an average rating of “Buy” by the six research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several brokerages recently weighed in on APYX. TheStreet lowered Tribune Publishing from a “c-” rating to a “d+” rating in a report on Monday, May 20th. JMP Securities set a $146.00 price objective on Hubbell and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Dougherty & Co decreased their price objective on Apyx Medical from $12.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. ValuEngine lowered China Southern Airlines from a “hold” rating to a “sell” rating in a report on Monday, April 29th. Finally, Zacks Investment Research lowered Guardant Health from a “hold” rating to a “sell” rating in a report on Monday, March 18th.

NASDAQ APYX opened at $7.00 on Thursday. Apyx Medical has a one year low of $3.55 and a one year high of $8.89. The business’s fifty day simple moving average is $6.39.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04. Apyx Medical had a negative return on equity of 12.25% and a net margin of 224.06%. The company had revenue of $5.82 million for the quarter. On average, research analysts predict that Apyx Medical will post -0.69 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rehmann Capital Advisory Group purchased a new position in Apyx Medical during the 1st quarter valued at about $61,000. Menta Capital LLC purchased a new position in Apyx Medical during the 1st quarter valued at about $65,000. Sheaff Brock Investment Advisors LLC purchased a new position in Apyx Medical during the 1st quarter valued at about $66,000. Steward Partners Investment Advisory LLC purchased a new position in Apyx Medical during the 1st quarter valued at about $68,000. Finally, WINTON GROUP Ltd purchased a new position in Apyx Medical during the 2nd quarter valued at about $79,000. 45.39% of the stock is owned by institutional investors.

Apyx Medical Company Profile

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Recommended Story: LIBOR

Receive News & Ratings for Apyx Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Apyx Medical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

One Group Hospitality Inc (NASDAQ:STKS) Given Consensus Recommendation of “Hold” by …

Vanguard Group Inc. raised its holdings in shares of One Group Hospitality Inc (NASDAQ:STKS) by 8.2% in the 3rd quarter, according to its most …

One Group Hospitality logoOne Group Hospitality Inc (NASDAQ:STKS) has been given a consensus recommendation of “Hold” by the six analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $4.50.

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of One Group Hospitality from a “hold” rating to a “sell” rating in a report on Tuesday, May 7th. ValuEngine raised shares of One Group Hospitality from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. TheStreet cut shares of One Group Hospitality from a “b-” rating to a “c” rating in a research note on Thursday, May 16th. Finally, Loop Capital assumed coverage on shares of One Group Hospitality in a research note on Thursday, April 4th. They set a “buy” rating for the company.

STKS stock traded up $0.03 during mid-day trading on Friday, hitting $3.23. 87,651 shares of the company were exchanged, compared to its average volume of 31,401. The company has a debt-to-equity ratio of 4.82, a quick ratio of 0.47 and a current ratio of 0.54. The company has a market capitalization of $90.75 million, a P/E ratio of 26.92 and a beta of 0.73. One Group Hospitality has a 1-year low of $1.87 and a 1-year high of $4.00.

One Group Hospitality (NASDAQ:STKS) last announced its earnings results on Thursday, May 9th. The restaurant operator reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. The firm had revenue of $22.78 million for the quarter, compared to the consensus estimate of $21.80 million. One Group Hospitality had a net margin of 4.39% and a return on equity of 37.64%. Analysts forecast that One Group Hospitality will post 0.18 earnings per share for the current year.

An institutional investor recently raised its position in One Group Hospitality stock. Vanguard Group Inc. raised its holdings in shares of One Group Hospitality Inc (NASDAQ:STKS) by 8.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 328,662 shares of the restaurant operator’s stock after acquiring an additional 24,878 shares during the quarter. Vanguard Group Inc. owned approximately 1.16% of One Group Hospitality worth $1,160,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.83% of the company’s stock.

One Group Hospitality Company Profile

The ONE Group Hospitality, Inc, a hospitality company, develops, owns, and operates restaurants and lounges worldwide. It operates in three segments: Owned Restaurants; Owned Food, Beverage and Other; and Managed and Licensed Operations. The company also provides turn-key food and beverage services for hospitality venues, including hotels, casinos, and other locations.

Featured Story: What causes a recession?

Receive News & Ratings for One Group Hospitality Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for One Group Hospitality and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts